Tobacco Turning out to be the Hero For Covid-19
British American Tobacco
The second largest manufacturer of cigarettes, has recently claimed that their tobacco-based vaccine against Covid-19 was now ready for human trials after getting the requisite approval from the United States Food and Drug Administration (FDA).
In a statement on Friday, the firm said its experimental vaccine “has been shown to produce a positive immune response” in pre-clinical testing.
The vaccine is based on an artificially built fragment of the novel coronavirus, called an “antigen”, which is inserted into tobacco plants for reproduction. Once the plants were harvested, the antigen was then purified.
This antigen, which is essentially a component of the novel coronavirus, would generate an immune response from the body when administered to human beings, the statement had said.
According to the report, a group of monkeys was exposed to the SARS-CoV-2 virus. After they were given the vaccine, the six animals had less of the virus in their lungs and airways. The development holds promise as rhesus macaques have similar immune systems to humans.
The vaccine appeared to protect the animals against developing pneumonia. Moreover, the animals also didn’t develop “immune-enhanced disease” – when the vaccine triggers a worse response to a disease.
Inovio Pharmaceuticals
An US-based biotechnology company, recently announced it had enrolled 40 healthy volunteers for its phase 1 trial and expects preliminary data on safety and immune response in late June. In its studies on animals, Inovio said its coronavirus vaccine produced strong antibody and T-cell responses.
A US media report said participants were receiving two doses of vaccine, four weeks apart. The Inovio vaccine focuses on the use of optimized DNA plasmids. Through computer sequencing, these small circles of double-stranded DNA are reorganized to produce a specific immune response in the body. Inovio then delivers these plasmids intradermally or intramuscularly through the company’s own hand-held smart device.
CanSino Biologics Inc.
A China-based company, has announced a tie-up with Canadian National Research Council on clinical trials of its Recombinant Novel Coronavirus Vaccine (Ad5-nCoV). The Ad5-nCoV vaccine is the first to enter the second phase of human clinical trials and has been listed by WHO as one of the top contenders.
Ad5-nCoV is a genetically engineered vaccine candidate with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein, which intends to be used to prevent the disease caused by Covid-19. CanSino Biologics Inc has already manufactured an approved vaccine for Ebola.
Comments
Post a Comment
If Anybody Have Any Doubt Please Let Me Know. thank you